Method for synchronously detecting colistin sulfate and doxycycline hydrochloride in compound preparation
By optimizing the high-performance liquid chromatography conditions, a method for synchronous detection of colistin sulfate and doxycycline hydrochloride in compound injections was established, which solved the lack of these two components in the prior art and achieved efficient and low-cost quality control.
Patent Information
- Application Number
- CN202510896811.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-30
- Publication Date
- 2025-09-02
AI Technical Summary
The prior art lacks a high-performance liquid chromatography method that simultaneously detects the content of two active ingredients in compound injections.
By optimizing the high-performance liquid chromatography conditions, including mobile phase composition, gradient elution procedures and detection parameters, a method for synchronous detection of colistin sulfate and doxycycline hydrochloride was established, and the standard series of solutions was detected using high-performance liquid chromatography, a standard curve was drawn, and the peak area of the sample solution was substituted into the standard curve to obtain concentration values.
The simultaneous detection of doxycycline hydrochloride and multiple colistin sulfate within 15 minutes was achieved, which significantly reduced time and reagent consumption, and provided an efficient and low-cost quality control solution.
Smart Images

Figure CN120577440A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of analytical chemistry, and in particular to a method for synchronously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation. Background Art
[0002] High-performance liquid chromatography (HPLC) is a key analytical method included in the veterinary pharmacopoeia. Due to its excellent resolution, sensitivity, and reproducibility, it has become a core analytical technology for pharmaceutical quality control. HPLC plays a vital role in drug development and production, and is widely used for accurate quantitative analysis of active ingredients in pharmaceutical formulations, impurity detection, and stability studies to ensure drug safety, efficacy, and consistency.
[0003] Compared to complex biological matrices such as animal tissue and plasma, pharmaceutical formulations have relatively simple matrices and generally do not require complex pretreatment processes, making HPLC method development and optimization more efficient. However, certain excipient components in different dosage forms, such as fillers in tablets, antioxidants in injections, or ointment base components, may interfere with chromatographic analysis, and this interference must be fully considered during method development. Furthermore, the quality evaluation of pharmaceutical formulations is a critical step in the R&D process, and its results provide important evidence for subsequent animal testing and clinical use. By testing key indicators such as the formulation's appearance, pH, content, and visible foreign matter, not only can product quality be effectively controlled but also preliminary predictions of in vivo efficacy can be made. Prior art doxycycline hydrochloride and colistin sulfate compound injections have a broad pathogen spectrum, effectively addressing the poor stability and high toxicity and side effects of existing similar injections. This injection represents a veterinary injection product with excellent stability, low toxicity and side effects, and significant efficacy, offering broad application prospects. However, there is no HPLC method in the art for simultaneously detecting the contents of the two active ingredients, doxycycline hydrochloride and colistin sulfate, in a compound injection. Therefore, there is an urgent need for an HPLC method that can simultaneously detect the contents of the two active ingredients, colistin sulfate and doxycycline hydrochloride, in a compound injection. Summary of the Invention
[0004] The present invention aims to provide a method for the simultaneous detection of colistin sulfate and doxycycline hydrochloride in a compound preparation. This technical solution establishes an HPLC detection method for the two key components in the compound injection. By systematically optimizing chromatographic conditions and quality evaluation, it aims to establish a scientific and reliable quality control scheme, providing a methodological reference for the analysis of similar preparations.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides a method for synchronously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation, the method comprising the following steps:
[0007] (1) Prepare the mobile phase;
[0008] (2) preparing a standard series of colistin sulfate solutions and a standard series of doxycycline hydrochloride solutions, testing the standard series of solutions using high performance liquid chromatography, and drawing a standard curve of colistin sulfate and a standard curve of doxycycline hydrochloride;
[0009] (3) Prepare the sample solution to be loaded on the machine;
[0010] (4) The sample solution to be loaded is detected by high performance liquid chromatography, and the peak areas of colistin sulfate and doxycycline hydrochloride are substituted into the standard curve obtained in step (2) to obtain the concentration values of colistin sulfate and doxycycline hydrochloride in the sample solution to be loaded.
[0011] Preferably, the mobile phase in step (1) comprises mobile phase A and mobile phase B, wherein the mobile phase A is a 0.055-0.065% TFA dilute solution, and the mobile phase B is acetonitrile.
[0012] Preferably, the mobile phase gradient elution conditions of the high performance liquid chromatography in step (2) and step (4) are: 0 min, 70-78% mobile phase A and 22-30% mobile phase B; 10 min, 34-38% mobile phase A and 62-66% mobile phase B; 10.10 min, 70-80% mobile phase A and 20-30% mobile phase B; 15.00 min, 60-70% mobile phase A and 30-40% mobile phase B.
[0013] Preferably, the mobile phase flow rate of the high performance liquid chromatography in step (2) and step (4) is 0.8 to 1.2 mL / min, the detection system of the high performance liquid chromatography is 1260Ⅱ Prime LC, the injection volume of the sample solution on the high performance liquid chromatography machine is 4 to 6 μL, and the wavelength of the ultraviolet detector of the high performance liquid chromatography is 210 to 220 nm.
[0014] Preferably, the HPLC column model in step (2) and step (4) is Poroshell 120SB-C18, the inner diameter of the HPLC column is 4 to 5 mm, the column length of the HPLC column is 95 to 105 mm, the particle size of the HPLC column filler is 2 to 3 μm, the column temperature of the HPLC column is 28 to 32° C., and the column pressure of the HPLC column is 250 to 260 bar.
[0015] Preferably, the concentrations of the colistin sulfate standard series solutions in step (2) are 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, and 700 μg / mL, respectively; the concentrations of the doxycycline hydrochloride and colistin sulfate standard series solutions are 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, and 800 μg / mL, respectively.
[0016] Preferably, the colistin sulfate in step (2) and step (4) includes colistin sulfate A and colistin sulfate B, the retention time of the colistin sulfate A is 4.8 min, the retention time of the colistin sulfate B is 4.3 min, and the retention time of the doxycycline hydrochloride is 5.8 min.
[0017] The present invention also provides application of the method in simultaneously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation.
[0018] The beneficial effects of the present invention are:
[0019] The HPLC method for the simultaneous detection of colistin sulfate and doxycycline hydrochloride in a compound injection provided by the present invention can simultaneously detect doxycycline hydrochloride and multiple colistin sulfates by optimizing the gradient elution procedure in traditional detection methods. Sample detection can be completed in 15 minutes, significantly reducing time costs and reagent consumption. This provides veterinary drug manufacturers and regulatory agencies with an efficient, low-cost quality control solution with direct industrial promotion value. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the standard curve of colistin sulfate concentration-peak area;
[0021] Figure 2 HPLC chromatogram of blank solvent (20% acetonitrile aqueous solution);
[0022] Figure 3 is the HPLC chromatogram of colistin sulfate standard (500 μg / mL);
[0023] Figure 4 is the HPLC chromatogram of the blank excipient solution;
[0024] Figure 5 This is the HPLC chromatogram of the compound injection;
[0025] Figure 6 This is the chromatogram of the recovery test of colistin sulfate (addition range 80% to 120%);
[0026] Figure 7 This is the standard curve of doxycycline hydrochloride concentration-peak area;
[0027] Figure 8 HPLC chromatogram of doxycycline hydrochloride standard (600 μg / mL);
[0028] Figure 9 This is the chromatogram of the recovery test of doxycycline hydrochloride (addition range 80% to 120%). DETAILED DESCRIPTION
[0029] The present invention provides a method for synchronously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation, the method comprising the following steps:
[0030] (1) Prepare the mobile phase;
[0031] (2) preparing a standard series of colistin sulfate solutions and a standard series of doxycycline hydrochloride solutions, testing the standard series of solutions using high performance liquid chromatography, and drawing a standard curve of colistin sulfate and a standard curve of doxycycline hydrochloride;
[0032] (3) Prepare the sample solution to be loaded on the machine;
[0033] (4) The sample solution to be loaded is detected by high performance liquid chromatography, and the peak areas of colistin sulfate and doxycycline hydrochloride are substituted into the standard curve obtained in step (2) to obtain the concentration values of colistin sulfate and doxycycline hydrochloride in the sample solution to be loaded.
[0034] In the present invention, the mobile phase in step (1) preferably includes mobile phase A and mobile phase B, the mobile phase A is preferably a 0.055-0.065% TFA dilute solution, more preferably a 0.06% TFA dilute solution, and the mobile phase B is preferably acetonitrile.
[0035] In the present invention, the mobile phase gradient elution conditions of the high performance liquid chromatography in step (2) and step (4) are preferably: 0 min, 70-78% mobile phase A and 22-30% mobile phase B; 10 min, 34-38% mobile phase A and 62-66% mobile phase B; 10.10 min, 70-80% mobile phase A and 20-30% mobile phase B; 15.00 min, 60-70% mobile phase A and 30-40% mobile phase B;
[0036] Further preferred is: 0 min, 75% mobile phase A and 25% mobile phase B; 10 min, 35% mobile phase A and 65% mobile phase B; 10.10 min, 75% mobile phase A and 25% mobile phase B; 15.00 min, 65% mobile phase A and 35% mobile phase B.
[0037] In the present invention, the mobile phase flow rate of the high performance liquid chromatography in step (2) and step (4) is preferably 0.8 to 1.2 mL / min, more preferably 1.0 mL / min, the detection system of the high performance liquid chromatography is preferably 1260ⅡPrimeLC, the injection volume of the sample solution on the high performance liquid chromatography is preferably 4 to 6 μL, more preferably 5 μL, and the wavelength of the ultraviolet detector of the high performance liquid chromatography is preferably 210 to 220 nm, more preferably 215 nm.
[0038] In the present invention, the chromatographic column model of the HPLC method in step (2) and step (4) is preferably Poroshell 120SB-C18, the inner diameter of the chromatographic column of the HPLC method is preferably 4-5 mm, more preferably 4.6 mm, the column length of the chromatographic column of the HPLC method is preferably 95-105 mm, more preferably 100 mm, the particle size of the chromatographic column packing of the HPLC method is preferably 2-3 μm, more preferably 2.7 μm, the column temperature of the HPLC method is preferably 28-32° C., more preferably 30° C., and the column pressure of the HPLC method is preferably 250-260 bar, more preferably 255 bar.
[0039] In the present invention, the drift tube temperature of the evaporative light scattering detector of the high performance liquid chromatography in step (2) and step (4) is preferably 58-62°C, more preferably 60°C, the nebulizer temperature of the evaporative light scattering detector of the high performance liquid chromatography is preferably 58-62°C, more preferably 60°C, the frequency of the evaporative light scattering detector of the high performance liquid chromatography is preferably 38-42Hz, more preferably 40Hz, the evaporative light scattering detector of the high performance liquid chromatography.
[0040] In the present invention, the concentrations of the colistin sulfate standard series solutions in step (2) are preferably 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, and 700 μg / mL, respectively; the concentrations of the doxycycline hydrochloride and colistin sulfate standard series solutions are preferably 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, and 800 μg / mL, respectively.
[0041] In the present invention, the colistin sulfate in step (2) and step (4) preferably includes colistin sulfate A and colistin sulfate B, the retention time of the colistin sulfate A is preferably 4.8 min, the retention time of the colistin sulfate B is preferably 4.3 min, and the retention time of the doxycycline hydrochloride is preferably 5.8 min.
[0042] The present invention also provides application of the method in simultaneously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation.
[0043] The instruments and sources used in the present invention are shown in Table 1, and the reagents and sources are shown in Table 2.
[0044] Table 1 Instruments and sources
[0045] instrument company Agilent HPLC 1260 Agilent Technologies (China) Co., Ltd. C18 column Agilent Technologies (China) Co., Ltd. Percentile electronic analytical balance Beijing Ohaus Co., Ltd. 10,000th electronic analytical balance SartoriusAnalytic, Inc. micropipette Eppendorf, Germany Solvent filters Tianjin Jinteng Experimental Equipment Co., Ltd. WH-I Micro Vortex Mixer Shanghai Huxi Analytical Instrument Factory Milli-Q Ultrapure Water Analyzer Millipore Corporation Electronic analytical balance SartoriusAnalytic, Inc. Disposable sterile syringe (2.5mL) Shanghai Zhiyu Medical Equipment Co., Ltd. Microporous filter membrane (0.22μm), injection vial, cap Tianjin Jinteng Experimental Equipment Co., Ltd.
[0046] Table 2 Reagents and sources
[0047]
[0048]
[0049] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0050] Example 1 HPLC chromatographic conditions
[0051] HPLC chromatography detection system: 1260ⅡPrime LC;
[0052] UV detector wavelength: 215nm;
[0053] Column model: Poroshell 120SB-C18, 4.6*100mm, 2.7μm;
[0054] Mobile phase A: 0.06% TFA dilute solution (measure 1000 mL of ultrapure water, add 0.6 mL of trifluoroacetic acid, mix, place on a magnetic stirrer, stir for 15 minutes, and filter to obtain the filtrate);
[0055] Mobile phase B: acetonitrile;
[0056] Mobile phase C: 50% acetonitrile in water (for column flushing and maintaining column efficiency);
[0057] Mobile phase D: 90% methanol in water (for column flushing and maintaining column efficiency).
[0058] Flow rate: 1 mL / min;
[0059] Injection volume: 5 μL;
[0060] Column temperature: 30°C;
[0061] Column pressure: 255 bar;
[0062] ELSD: 60℃, 60℃, 40Hz.
[0063] Table 3 HPLC mobile phase gradient elution conditions
[0064] Time (min) Flow rate (mL / min) 0.06% TFA dilute solution Acetonitrile 0.00 1.00 75 25 10.00 1.00 35 65 10.10 1.00 75 25 15.00 1.00 65 35
[0065] Example 2 Preparation of Colistin Sulfate Standard Stock Solution
[0066] Accurately weigh 51.76 mg of colistin sulfate standard and pour it into a 10 mL volumetric flask. Add 20% acetonitrile aqueous solution to dissolve and dilute to 10 mL to prepare a 5 mg / mL standard stock solution. Aliquot into 2 mL centrifuge tubes, seal and store at 4°C.
[0067] Example 3 Colistin sulfate standard curve drawing
[0068] The 5 mg / mL colistin sulfate standard stock solution prepared in Example 2 was diluted with 20% acetonitrile aqueous solution to 200, 300, 400, 500, 600, and 700 μg / mL colistin sulfate standard solutions. A 10 mL volumetric flask was used to make the volume. After preparation, 1 mL of the filtered standard solution was added to the injection vial using a 2.5 mL sterile syringe and a 0.22 μm sterile microporous filter membrane. Analysis was performed according to the HPLC chromatographic conditions of Example 1. Each concentration level was measured in parallel 3 times. A standard curve was established with the standard concentration as the independent variable (x) and the peak area as the dependent variable (y).
[0069] Based on the HPLC analysis data, a standard curve of colistin sulfate concentration (x, 0-700 μg / mL) and peak area (y) was established ( Figure 1 ). After linear regression analysis, the equation was obtained: y=1.106x+5.970(R 2 =0.9992), and the linear relationship was good within the determination range (Note: the peak area of colistin sulfate here is the sum of the peak area of colistin sulfate A and the peak area of colistin sulfate B).
[0070] Example 4 Colistin Sulfate Method Specificity
[0071] A blank solvent (20% acetonitrile aqueous solution), a colistin sulfate standard (500 μg / mL), a blank excipient solution prepared according to the following preparation process, and a compound injection were used as four sample solutions.
[0072] The raw materials and preparation method of the compound injection are as follows: each 1000 mL of the compound injection contains 30 g of doxycycline hydrochloride, 15 g of colistin sulfate, 2 g of L-ascorbic acid, 2 g of sodium metabisulfite, 240 mL of polyethylene glycol 400, 240 mL of 1,2-propylene glycol, and 26.4 g of magnesium chloride hexahydrate, with the balance being water for injection.
[0073] The preparation method of the above-mentioned compound injection comprises the following steps:
[0074] Step 1: Heat water for injection to 50°C, add L-ascorbic acid and sodium metabisulfite, and stir at 1200 r / min for 2 min until dissolved to obtain Solution 1;
[0075] Step 2: Add polyethylene glycol 400 and 1,2-propylene glycol to the obtained solution 1 at 50°C, stir at 1200 r / min for 5 minutes until the mixture becomes viscous, add magnesium chloride hexahydrate and dissolve it to obtain solution 2;
[0076] Step 3: At 50°C, doxycycline hydrochloride was added to solution 2, and the mixture was mixed at a speed of 1200 r / min for 15 minutes to complete the complexation reaction between doxycycline hydrochloride and magnesium chloride hexahydrate, until the doxycycline hydrochloride was dissolved into a light yellow liquid, to obtain solution 3.
[0077] Step 4: At 50°C, add colistin sulfate to solution 3 in small amounts several times, with 2.5 g added each time, for a total of 6 times. Continue stirring at 1200 r / min for 30 min until all the colistin sulfate is dissolved to obtain solution 4.
[0078] Step 5: After adjusting the pH of solution 4 to 4.0 with 5 mol / L sodium hydroxide solution, the solution was filtered twice with a 0.22 μM microporous membrane;
[0079] Step 6: The filtrate obtained in step 5 is filled into a 5 mL vial, sealed with a disposable graded rubber stopper and an aluminum-plastic combination cap, and then filled to obtain the injection solution, i.e., the compound injection solution.
[0080] The raw materials and preparation method of the blank excipient solution are as follows: remove "30g of doxycycline hydrochloride and 15g of colistin sulfate" in the compound injection, and the remaining raw materials and preparation method are the same as those of the compound injection.
[0081] Sample solution preparation method: Take 20 μL of sample solution, dilute to 1 mL with 20% acetonitrile aqueous solution, thoroughly vortex mix, and add 1 mL of filtrate to the sample vial using a 2.5 mL sterile syringe and a 0.22 μm sterile microporous filter. The colistin sulfate HPLC chromatographic conditions of Example 1 were used to determine whether the excipients and solvents would interfere with the drug peak of colistin sulfate.
[0082] Results: The HPLC chromatograms of blank solvent (20% acetonitrile aqueous solution), colistin sulfate standard, blank excipient solution and colistin sulfate in compound injection are shown in Figure 2. Figure 2 、 3 , 4, 5. From Figures 2 to 5It can be seen that the retention times of the two main components in colistin sulfate (colistin sulfate A and colistin sulfate B) are 4.8 min and 4.3 min, respectively, with good separation; no interference peaks appear in the chromatograms of blank solvent and blank excipient solution, indicating that the method has good specificity.
[0083] Example 5 Determination of Recovery and Precision of Colistin Sulfate
[0084] Prepare three concentration gradients of colistin sulfate sample solutions of 12, 15 and 18 mg / mL respectively. The sample solutions were treated according to the following treatment method: 20 μL of each concentration sample solution was taken, diluted to 1 mL with 20% acetonitrile aqueous solution, and thoroughly vortexed and mixed. After that, 1 mL of filtrate was added to the sample vial using a 2.5 mL sterile syringe and a 0.22 μm sterile microporous filter membrane. The colistin sulfate HPLC chromatographic conditions of Example 1 were used for determination. Among them, 9 portions of each concentration were prepared in parallel, and the measurement was continued for 3 days. The recovery and precision (intraday and interday) were calculated: [the sample solution was prepared on the first day and stored at 4°C. The detection was done on day 1, day 2, day 3, and three parallel measurements (solution prepared on the first day) were made every day], see Table 4.
[0085] The HPLC chromatogram of the recovery test of colistin sulfate in compound injection is as follows Figure 6 As shown, it can be seen that the retention times of colistin A and B are similar to those of the standard ( Figure 3 ). As shown in Table 4, within the addition range of 80% to 120%, the average recovery of colistin sulfate was 98.32% to 101.39%, with an intra-day RSD of 0.79% to 1.89% (n=6) and an inter-day RSD of 0.34% to 1.40% (n=18). All results met the requirements of the Chinese Veterinary Pharmacopoeia for the content determination of preparations (recovery 95% to 105%, RSD ≤ 2%).
[0086] Table 4 Recovery and precision test results of colistin sulfate
[0087]
[0088] Example 6 Determination of colistin sulfate content
[0089] Three different batches of compound injection were prepared on October 22, 2024, October 23, 2024, and October 24, 2024, respectively, according to the raw materials and preparation method of the compound injection in Example 4.
[0090] The results of the determination of the colistin sulfate content in three different batches of compound injection are shown in Table 5. The content of colistin sulfate in three different batches of colistin sulfate and doxycycline hydrochloride compound injection is 98.33% to 99.06%, which is in line with the requirements of the "Pharmacopoeia of Veterinary People's Republic of China".
[0091] Table 5 Determination results of colistin sulfate content in compound injection
[0092]
[0093] Example 7 Preparation of Doxycycline Hydrochloride Standard Stock Solution
[0094] Accurately weigh 50.00 mg of colistin sulfate standard into a 10 mL volumetric flask, add 20% acetonitrile aqueous solution to dissolve, and dilute to 10 mL with 20% acetonitrile aqueous solution to prepare a 5 mg / mL standard stock solution. Aliquot into 2 mL centrifuge tubes, seal, and store at 4°C.
[0095] Example 8 Doxycycline hydrochloride standard curve drawing
[0096] The 5 mg / mL doxycycline hydrochloride stock standard solution prepared in Example 7 was diluted with a 20% acetonitrile aqueous solution and brought to volume to a concentration of 300, 400, 500, 600, 700, and 800 μg / mL. A 10 mL volumetric flask was used to bring the solution to volume. After preparation, 1 mL of the filtered standard solution was added to a sample vial using a 2.5 mL sterile syringe and a 0.22 μm sterile microporous filter membrane. Analysis was performed according to the HPLC chromatographic conditions of Example 1, with three replicates performed at each concentration level. A standard curve was established using the standard concentration as the independent variable (x) and the peak area as the dependent variable (y).
[0097] Based on the HPLC analysis data, a standard curve of doxycycline hydrochloride concentration (x, 0-800 μg / mL) and peak area (y) was established ( Figure 7 ). After linear regression analysis, the equation y=3.541x-32.90(R 2 =0.9994), and the linear relationship was good within the measurement range.
[0098] Example 9 Doxycycline Hydrochloride Method Specificity
[0099] A blank solvent (20% acetonitrile aqueous solution), a doxycycline hydrochloride standard (600 μg / mL), a blank excipient solution prepared according to the following preparation process, and a compound injection were used as four sample solutions.
[0100] The raw materials and preparation method of the compound injection are the same as those in Example 4;
[0101] The raw materials and preparation method of the blank auxiliary material solution are the same as those in Example 4.
[0102] The sample solution was processed as in Example 4.
[0103] Conclusion: The HPLC chromatogram of doxycycline hydrochloride standard is shown in Figure 8 The HPLC chromatograms of blank solvent (20% acetonitrile aqueous solution), blank excipient solution and doxycycline hydrochloride in compound injection are shown in Figure 1. Figure 2 、 4 、5. Figure 2 、 4 The comparison results of , 5, and 8 showed that the retention time of doxycycline hydrochloride was about 5.8 min, and the peak shape was symmetrical; the blank solvent and excipients did not produce any interfering peaks, and the method had good specificity.
[0104] Example 10 Recovery and Precision Determination of Doxycycline Hydrochloride
[0105] Three concentration gradients of 12, 15, and 18 mg / mL of doxycycline hydrochloride sample solutions were prepared. The sample solutions were processed in the same manner as in Example 5. The results are shown in Table 6.
[0106] Conclusion: The HPLC chromatogram of the sample recovery test of doxycycline hydrochloride in the compound injection is shown in Figure 9 , it can be seen that the retention time of doxycycline hydrochloride is similar to that of the standard ( Figure 8 ). As shown in Table 6, within the addition range of 80% to 120%, the average recovery of doxycycline hydrochloride was 96.66% to 101.34%, with an intra-day RSD of 0.029% to 0.59% (n=6) and an inter-day RSD of 0.42% to 1.64% (n=18). All results met the requirements of the Chinese Veterinary Pharmacopoeia for the content determination of preparations (recovery 95%-105%, RSD ≤ 2%).
[0107] Table 6 Recovery and precision test results of doxycycline hydrochloride
[0108]
[0109] Example 11 Determination of doxycycline hydrochloride content
[0110] The doxycycline hydrochloride content was determined using three different batches of the compound injection prepared in Example 6. The determination results are shown in Table 7. The doxycycline hydrochloride content in the three different batches of colistin sulfate and doxycycline hydrochloride compound injection was 103.43% to 104.06%, which meets the requirements of the Veterinary Pharmacopoeia of the People's Republic of China.
[0111] Table 7 Determination results of doxycycline hydrochloride content in compound injection
[0112]
[0113] As can be seen from the above embodiments, the present invention provides a method for synchronously detecting colistin sulfate and doxycycline hydrochloride in a compound preparation, comprising the following steps: (1) preparing a mobile phase; (2) preparing a standard series of colistin sulfate solutions and a standard series of doxycycline hydrochloride solutions, detecting the standard series solutions using high performance liquid chromatography, and drawing a standard curve for colistin sulfate and a standard curve for doxycycline hydrochloride; (3) preparing a sample solution to be loaded on the machine; (4) detecting the sample solution to be loaded on the machine using high performance liquid chromatography, substituting the peak areas of colistin sulfate and doxycycline hydrochloride into the standard curve obtained in step (2) to obtain the concentration values of colistin sulfate and doxycycline hydrochloride in the sample solution to be loaded on the machine. This technical solution can simultaneously detect doxycycline hydrochloride and multiple colistin sulfates by optimizing the gradient elution procedure, and can complete sample detection in 15 minutes, significantly reducing time cost and reagent consumption.
[0114] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for simultaneous detection of colistin sulfate and doxycycline hydrochloride in a compound preparation, characterized in that: The method comprises the following steps: (1) Prepare the mobile phase; (2) preparing a standard series of colistin sulfate solutions and a standard series of doxycycline hydrochloride solutions, testing the standard series of solutions using high performance liquid chromatography, and drawing a standard curve of colistin sulfate and a standard curve of doxycycline hydrochloride; (3) Prepare the sample solution to be loaded on the machine; (4) The sample solution to be loaded is detected by high performance liquid chromatography, and the peak areas of colistin sulfate and doxycycline hydrochloride are substituted into the standard curve obtained in step (2) to obtain the concentration values of colistin sulfate and doxycycline hydrochloride in the sample solution to be loaded.
2. The method according to claim 1, characterized in that The mobile phase in step (1) includes mobile phase A and mobile phase B, wherein the mobile phase A is a 0.055-0.065% TFA dilute solution, and the mobile phase B is acetonitrile.
3. The method according to claim 2, characterized in that The mobile phase gradient elution conditions of the high performance liquid chromatography in step (2) and step (4) are: 0 min, 70-78% mobile phase A and 22-30% mobile phase B; 10 min, 34-38% mobile phase A and 62-66% mobile phase B; 10.10 min, 70-80% mobile phase A and 20-30% mobile phase B; 15.00 min, 60-70% mobile phase A and 30-40% mobile phase B.
4. The method according to claim 3, characterized in that The mobile phase flow rate of the high performance liquid chromatography method in step (2) and step (4) is 0.8 to 1.2 mL / min, the detection system of the high performance liquid chromatography method is 1260Ⅱ Prime LC, the injection volume of the sample solution on the high performance liquid chromatography method is 4 to 6 μL, and the wavelength of the ultraviolet detector of the high performance liquid chromatography method is 210 to 220 nm.
5. The method according to claim 4, characterized in that The HPLC column model in step (2) and step (4) is Poroshell 120SB-C18, the inner diameter of the HPLC column is 4-5 mm, the column length is 95-105 mm, the particle size of the HPLC column filler is 2-3 μm, the column temperature is 28-32° C., and the column pressure is 250-260 bar.
6. The method according to claim 5, characterized in that The concentrations of the colistin sulfate standard series solutions in step (2) are 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, and 700 μg / mL, respectively; the concentrations of the doxycycline hydrochloride and colistin sulfate standard series solutions are 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, and 800 μg / mL, respectively.
7. The method according to claim 6, characterized in that The colistin sulfate in step (2) and step (4) includes colistin sulfate A and colistin sulfate B, the retention time of the colistin sulfate A is 4.8 min, the retention time of the colistin sulfate B is 4.3 min, and the retention time of the doxycycline hydrochloride is 5.8 min.
8. Use of the method according to any one of claims 1 to 7 for the simultaneous detection of colistin sulfate and doxycycline hydrochloride in a compound preparation.
